138 related articles for article (PubMed ID: 35648430)
1. Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series.
Enevold C; Loft N; Bregnhøj A; Zachariae C; Iversen L; Skov L; Nielsen CH
JAMA Dermatol; 2022 Jul; 158(7):762-769. PubMed ID: 35648430
[TBL] [Abstract][Full Text] [Related]
2. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
5. Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis.
Elgaard CDB; Iversen L; Hjuler KF
Drugs R D; 2023 Jun; 23(2):155-163. PubMed ID: 37155121
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
Lebwohl MG; Blauvelt A; Menter A; Papp KA; Guenthner S; Pillai R; Israel RJ; Jacobson A
Am J Clin Dermatol; 2019 Dec; 20(6):863-871. PubMed ID: 31493163
[TBL] [Abstract][Full Text] [Related]
7. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
Warren RB; Hansen JB; Reich K; Paul C; Puig L
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):450-457. PubMed ID: 32662540
[TBL] [Abstract][Full Text] [Related]
8. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
9. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy.
Galluzzo M; Caldarola G; De Simone C; Bernardini N; Moretta G; Pallotta S; Botti E; Campione E; Pirro F; Potenza C; Bianchi L; Peris K
Expert Opin Biol Ther; 2021 Sep; 21(9):1299-1310. PubMed ID: 34114515
[No Abstract] [Full Text] [Related]
10. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies.
Zachariae C; Mrowietz U; Strodl Andersen J; Puig L
Eur J Dermatol; 2022 Jul; 32(4):530-535. PubMed ID: 36301758
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
Seo SJ; Shin BS; Lee JH; Jeong H
J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study.
Imafuku S; Ohata C; Okubo Y; Tobita R; Saeki H; Mabuchi T; Hashimoto Y; Murotani K; Kitabayashi H; Kanai Y
J Dermatol Sci; 2022 Mar; 105(3):176-184. PubMed ID: 35248465
[TBL] [Abstract][Full Text] [Related]
13. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.
Fargnoli MC; Esposito M; Dapavo P; Parodi A; Rossi M; Tiberio R; Dastoli S; Offidani AM; Argenziano G; Gisondi P; Lo Schiavo A; Loconsole F; Pella P; Bardazzi F; Cusano F; Gattoni M; Nacca M; Cannavò SP; Pellegrini C; Costanzo A;
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):693-700. PubMed ID: 32916767
[TBL] [Abstract][Full Text] [Related]
14. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis).
Gargiulo L; Ibba L; Malagoli P; Amoruso F; Argenziano G; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Fabbrocini G; Franchi C; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Megna M; Sampogna F; Travaglini M; Costanzo A; Narcisi A
Front Med (Lausanne); 2023; 10():1196966. PubMed ID: 37469659
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis.
Loft N; Bregnhøj A; Fage S; Nielsen CH; Enevold C; Zachariae C; Iversen L; Skov L
Dermatol Ther; 2021 Nov; 34(6):e15106. PubMed ID: 34418225
[TBL] [Abstract][Full Text] [Related]
16. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
Reich K; Hansen JB; Puig L; Konstantinou MP; Warren RB
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2034-2044. PubMed ID: 34076919
[TBL] [Abstract][Full Text] [Related]
17. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
Kokolakis G; Vadstrup K; Hansen JB; Carrascosa JM
Dermatology; 2022; 238(4):620-629. PubMed ID: 34823247
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1).
Papp K; Menter A; Leonardi C; Soung J; Weiss S; Pillai R; Jacobson A
Br J Dermatol; 2020 Dec; 183(6):1037-1048. PubMed ID: 32286683
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
Reich K; Iversen L; Puig L; Lambert J; Mrowietz U; Kaplan Saday K; Warren RB
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1275-1283. PubMed ID: 35279890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
